PMCB vs TMUS · $8.6M cap vs P/E 19, rev $22.79B
PharmaCyte Biotech Inc (PMCB) versus T-Mobile US Inc (TMUS) — a side-by-side from cached financials, not a winner call.
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ.
T-Mobile US Inc (TMUS) is a telecom services company listed on NASDAQ. It is led by Mike Sievert.
Latest reported PMCB revenue for 2026-04-30 was $0. Net income was -$19.4M. PMCB currently screens at market cap $8.6M.
Latest reported TMUS revenue for 2026-06-30 was $22.79B. Net income was $3.24B. Revenue was down 1.4% from 2026-03-31 to 2026-06-30. TMUS currently screens at market cap $196.21B and trailing P/E 19.3.
PMCB currently screens at market cap $8.6M. TMUS currently screens at market cap $196.21B and trailing P/E 19.3.
Not investment advice. Open the PMCB and TMUS stock pages for the full models.
Not investment advice.